Radiation Oncology Basics — MCQs

Radiation Oncology Basics Indian Medical PG Practice Questions and MCQs

Question 51: Taste loss due to radiation therapy is recovered in approximately what timeframe?

A. 2 weeks
B. 60 - 120 weeks
C. 60 - 120 days (Correct Answer)
D. Not reversible

Explanation: **Explanation:** Radiation-induced dysgeusia (taste loss) is a common side effect in patients receiving radiotherapy for head and neck cancers. The underlying mechanism involves damage to the rapidly dividing basal cells of the taste buds and the microvilli of gustatory cells, which have a high turnover rate. **Why 60 - 120 days is correct:** Taste buds are highly radiosensitive. While taste impairment typically begins within the first 1-2 weeks of treatment (at doses around 10-20 Gy), the recovery process begins after the completion of radiotherapy. It takes approximately **2 to 4 months (60 - 120 days)** for the taste bud cells to regenerate and for the neural pathways to stabilize, leading to a significant restoration of taste function in most patients. **Analysis of Incorrect Options:** * **A. 2 weeks:** This is too early. While acute mucosal inflammation (mucositis) may begin to subside, the regeneration of specialized gustatory cells takes longer. * **B. 60 - 120 weeks:** This represents a timeframe of over 1-2 years. While some patients experience long-term changes, the majority of clinical recovery occurs much sooner. * **D. Not reversible:** Radiation-induced taste loss is generally reversible. Permanent loss (ageusia) is rare unless very high doses are delivered directly to the tongue or if there is severe, permanent xerostomia (dry mouth), as saliva is essential for tasting. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Taste Loss:** Sensitivity to **bitter and acid** flavors is usually lost first, while **salty and sweet** are lost later. * **Xerostomia Connection:** Damage to the salivary glands (especially the parotid) exacerbates taste loss because saliva acts as a solvent for food particles to reach taste receptors. * **Zinc Supplementation:** Some studies suggest that Zinc sulfate may help in the early recovery of taste post-radiation.

Question 52: Carcinoma responding maximally to radiotherapy is:

A. Squamous cell carcinoma
B. Adenocarcinoma
C. Small cell carcinoma (Correct Answer)
D. None of the above

Explanation: **Explanation:** The responsiveness of a tumor to radiotherapy is primarily determined by its **radiosensitivity**, which is closely linked to the **Bergonie-Tribondeau law**. This law states that cells are more radiosensitive if they have a high mitotic rate, a long mitotic future, and are undifferentiated. **1. Why Small Cell Carcinoma is Correct:** Small cell carcinoma (most commonly seen in the lung) is a highly undifferentiated, rapidly dividing neuroendocrine tumor. Due to its high growth fraction and rapid cell turnover, it is classified as **highly radiosensitive**. It shows a dramatic initial response to radiation (and chemotherapy), often leading to significant tumor shrinkage or "vanishing" on follow-up imaging. **2. Why Other Options are Incorrect:** * **Squamous Cell Carcinoma (SCC):** While SCC is considered **radiosensitive** and is frequently treated with radiotherapy (e.g., in head and neck or cervical cancers), its response is generally slower and less "maximal" compared to small cell variants. * **Adenocarcinoma:** These tumors are generally considered **radioresponsive to radioresistant**. They are more differentiated and have a slower cell cycle compared to small cell carcinoma, making them less susceptible to radiation-induced DNA damage. **High-Yield Clinical Pearls for NEET-PG:** * **Radiosensitivity Hierarchy:** * *Highly Radiosensitive:* Lymphoma, Leukemia, Seminoma, Dysgerminoma, Small Cell Carcinoma. * *Moderately Radiosensitive:* Squamous Cell Carcinoma. * *Radioresistant:* Osteosarcoma, Malignant Melanoma, Pancreatic Adenocarcinoma. * **Therapeutic Ratio:** The ratio of the maximum tolerated dose of normal tissue to the minimum dose required to kill the tumor. * **The 4 R’s of Radiobiology:** Repair, Reassortment, Repopulation, and Reoxygenation.

Question 53: Intraoperative radiation therapy is typically indicated for which of the following organs?

A. Pancreas (Correct Answer)
B. Breast
C. Cervix
D. Thyroid

Explanation: **Explanation:** **Intraoperative Radiation Therapy (IORT)** involves the delivery of a single, concentrated dose of ionizing radiation directly to the tumor bed during surgery, immediately after the tumor is resected. **Why Pancreas is the Correct Answer:** The primary advantage of IORT is the ability to physically displace or shield radiosensitive dose-limiting structures (like the small intestine, stomach, and liver) away from the radiation field. In **pancreatic adenocarcinoma**, achieving negative surgical margins is difficult due to proximity to major vessels. IORT is typically indicated here to sterilize microscopic residual disease in the retroperitoneum, where conventional external beam radiation (EBRT) would be limited by bowel toxicity. **Analysis of Incorrect Options:** * **Breast:** While IORT is an emerging option for early-stage breast cancer (e.g., TARGIT trials), it is considered an *alternative* to whole-breast irradiation in highly selected cases, rather than a "typical" or standard indication compared to its established role in deep-seated abdominal malignancies. * **Cervix:** Cervical cancer is primarily managed with EBRT and **Brachytherapy** (intracavitary). IORT is rarely used unless there is a specific pelvic sidewall recurrence. * **Thyroid:** Differentiated thyroid cancer is managed with surgery and **Radioactive Iodine (I-131) therapy**. Radiation is rarely used, and IORT has no standard role here. **High-Yield Clinical Pearls for NEET-PG:** * **Common IORT Indications:** Pancreatic cancer, locally advanced rectal cancer, and retroperitoneal sarcomas. * **Key Advantage:** Maximizes the "Therapeutic Ratio" by allowing a high dose to the target while sparing OARs (Organs at Risk). * **Radiation Type:** Usually delivered via mobile linear accelerators (electrons) or low-energy X-rays.

Question 54: Which type of lung tumour responds best to radiotherapy?

A. Small cell carcinoma (Correct Answer)
B. Squamous cell carcinoma
C. Adenocarcinoma
D. All respond equally well

Explanation: ### Explanation **1. Why Small Cell Carcinoma (SCLC) is the Correct Answer:** The responsiveness of a tumor to radiotherapy is primarily determined by its **growth fraction** and **mitotic rate**. Small cell carcinoma is characterized by a very high proliferation rate and rapid cell turnover. According to the **Law of Bergonié and Tribondeau**, cells that are rapidly dividing and undifferentiated are the most radiosensitive. Consequently, SCLC shows a dramatic initial response to both chemotherapy and radiotherapy (often referred to as being "exquisitely radiosensitive"). **2. Why the Other Options are Incorrect:** * **Squamous Cell Carcinoma:** While it is more sensitive to radiation than adenocarcinoma, it is significantly less sensitive than SCLC. It is often treated with radiotherapy in locally advanced stages, but the response is slower and less complete. * **Adenocarcinoma:** This is generally considered **radioresistant** compared to SCLC. It has a lower growth fraction and is often peripheral, making it more suitable for surgical resection rather than primary radiotherapy. * **All respond equally well:** This is incorrect because lung cancers are biologically heterogeneous. Non-Small Cell Lung Cancers (NSCLC)—which include Squamous and Adenocarcinoma—behave very differently from SCLC regarding treatment sensitivity. **3. Clinical Pearls for NEET-PG:** * **Radiosensitivity vs. Curability:** While SCLC is the most *radiosensitive* (shrinks the fastest), it is rarely *cured* by radiation alone because it tends to metastasize very early. * **Treatment of Choice:** For Limited-Stage SCLC, the standard of care is **Concurrent Chemoradiotherapy**. * **Prophylactic Cranial Irradiation (PCI):** Because SCLC frequently spreads to the brain and the blood-brain barrier limits chemotherapy, PCI is often used to prevent recurrence in patients who respond well to initial treatment. * **Order of Radiosensitivity in Lung Cancer:** Small Cell > Squamous Cell > Adenocarcinoma.

Question 55: What is the dose of radiation that leads to mucositis?

A. 1000 rads
B. 1500-2000 rads
C. 2500-3000 rads
D. 3500-4000 rads (Correct Answer)

Explanation: **Explanation:** Radiation-induced mucositis is a common acute complication of radiotherapy, particularly in head and neck cancers. It occurs due to the depletion of the basal cell layer of the oral mucosa, leading to inflammation, ulceration, and pain. **Why Option D is Correct:** The threshold for clinically significant mucositis typically begins after the third or fourth week of conventional fractionation (2 Gy/day). By this time, the cumulative dose reaches **3500–4000 rads (35–40 Gy)**. At this dosage, the rate of cell death in the mucosal epithelium exceeds the rate of regeneration, resulting in denudation and the formation of pseudomembranes. **Analysis of Incorrect Options:** * **Option A (1000 rads):** This is a low dose. While it may cause mild erythema, it is insufficient to cause the structural breakdown of the mucosa. * **Option B (1500–2000 rads):** At this stage (end of week 2), patients may experience "patchy mucositis" or soreness, but the classic confluent mucositis associated with the question's threshold is not yet fully established. * **Option C (2500–3000 rads):** This is an intermediate dose where symptoms intensify, but the peak incidence and severity of confluent mucositis are more characteristically seen at the 3500–4000 rads mark. **NEET-PG High-Yield Pearls:** * **Unit Conversion:** 100 rads = 1 Gray (Gy). Therefore, 4000 rads = 40 Gy. * **Early vs. Late Effects:** Mucositis is an **acute effect** (occurs during or within 90 days of treatment). Late effects include xerostomia and osteoradionecrosis. * **Management:** Treatment is primarily supportive (salt-soda rinses, topical anesthetics, and "Magic Mouthwash"). * **Radiosensitivity:** The oral mucosa is highly radiosensitive because it consists of rapidly dividing labile cells.

Question 56: Which of the following is not a radiotherapy equipment?

A. Betatron
B. Telecurie-cobalt unit
C. Linear accelerator
D. Thimble chamber (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Thimble chamber**. In radiotherapy, equipment is broadly classified into **treatment delivery units** (which produce or house the radiation source) and **dosimetry/quality assurance tools** (which measure the radiation dose). * **Why Thimble Chamber is the correct answer:** A thimble chamber is not a treatment machine; it is a **dosimetry instrument** (an ionization chamber). It is used by medical physicists to calibrate the output of radiotherapy machines and measure the absorbed dose in a phantom. It works by collecting ions produced by radiation within a small air-filled cavity. **Analysis of Incorrect Options:** * **A. Betatron:** A cyclic particle accelerator that uses magnetic induction to accelerate electrons to high energies. While largely replaced by modern Linacs, it was historically used for high-energy electron and X-ray therapy. * **B. Telecurie-cobalt unit:** A mainstay of external beam radiotherapy (EBRT) that uses a radioactive **Cobalt-60** source. It emits gamma rays (average energy 1.25 MeV) and is a "teletherapy" unit because the source is kept at a distance from the patient. * **C. Linear accelerator (LINAC):** The most common modern radiotherapy equipment. It uses high-frequency electromagnetic waves to accelerate charged particles (electrons) to high speeds, producing either high-energy electron beams or megavoltage X-rays (via a tungsten target). **High-Yield Clinical Pearls for NEET-PG:** * **Cobalt-60 Half-life:** 5.26 years (requires source replacement roughly every 5 years). * **LINAC Advantage:** Unlike Cobalt units, LINACs do not contain a permanent radioactive source; they produce radiation only when powered on. * **Brachytherapy:** Involves placing the source *inside* or *immediately adjacent* to the tumor (e.g., Cesium-137, Iridium-192). * **Ionization Chambers:** Besides the thimble chamber, the **Farmer-type chamber** is the "gold standard" for absolute dose calibration in clinics.

Question 57: Which of the following is the most radiosensitive tumor?

A. Ewing tumor (Correct Answer)
B. Hodgkin's disease
C. Carcinoma cervix
D. Malignant fibrous histiocytoma

Explanation: **Explanation:** Radiosensitivity refers to the relative susceptibility of cells, tissues, or tumors to the ionizing effects of radiation. In clinical oncology, tumors are categorized based on the dose required for local control. **1. Why Ewing Tumor is the correct answer:** Ewing tumor (a member of the Small Round Blue Cell Tumor family) is classified as **highly radiosensitive**. These tumors typically respond to relatively low doses of radiation (usually 40–50 Gy). Among the options provided, it represents the most sensitive category. In the hierarchy of radiosensitivity, lymphoid cells and germ cells are the most sensitive, followed by small round cell tumors like Ewing sarcoma and Wilms tumor. **2. Analysis of Incorrect Options:** * **Hodgkin's disease:** While also highly radiosensitive, in the context of comparative MCQ hierarchies for NEET-PG, Ewing sarcoma is often grouped with the most sensitive pediatric/embryonal tumors. However, note that both A and B are sensitive; Ewing is frequently the "textbook" answer for the most sensitive bone/soft tissue tumor. * **Carcinoma cervix:** This is considered **radioresponsive** (moderately sensitive). It requires much higher therapeutic doses (70–85 Gy) for curative intent compared to Ewing tumor. * **Malignant fibrous histiocytoma (MFH):** Now often termed Pleomorphic Undifferentiated Sarcoma, this is **radioresistant**. Soft tissue sarcomas generally require high doses and are primarily managed surgically because they do not regress easily with radiation alone. **Clinical Pearls for NEET-PG:** * **Most Radiosensitive Cell:** Lymphocyte (exception to the Law of Bergonie and Tribondeau as it is a mature cell). * **Most Radiosensitive Phase of Cell Cycle:** M phase (Mitosis), followed by G2. * **Most Radioresistant Phase:** Late S phase. * **Order of Radiosensitivity (High to Low):** Lymphoma/Leukemia > Seminoma/Dysgerminoma > Ewing Sarcoma > Wilms Tumor > Squamous Cell Carcinoma > Adenocarcinoma > Osteosarcoma > Melanoma/Glioblastoma.

Question 58: Emergency radiotherapy is indicated in which of the following conditions?

A. Superior vena cava syndrome (Correct Answer)
B. Pericardial tamponade
C. Increased intracranial pressure
D. Spinal cord compression

Explanation: **Explanation:** In radiation oncology, an "oncological emergency" refers to a condition where immediate radiotherapy is required to prevent death or irreversible organ damage. **1. Why Superior Vena Cava (SVC) Syndrome is the correct answer:** SVC syndrome occurs due to the compression of the superior vena cava, most commonly by mediastinal tumors (e.g., Small Cell Lung Cancer or Lymphoma). It presents with facial edema, venous distention in the neck, and dyspnea. **Emergency Radiotherapy** is the treatment of choice for chemo-resistant tumors or when a rapid symptomatic response is needed to relieve the obstruction and prevent life-threatening airway compromise or cerebral edema. **2. Why the other options are incorrect:** * **B. Pericardial Tamponade:** This is a surgical/medical emergency requiring immediate **pericardiocentesis** or a pericardial window. Radiotherapy is too slow to relieve the acute pressure of fluid on the heart. * **C. Increased Intracranial Pressure (ICP):** While radiotherapy is used for brain metastases, the immediate management of increased ICP involves **Dexamethasone**, IV Mannitol, or surgical shunting. Radiotherapy may actually cause a transient increase in edema initially. * **D. Spinal Cord Compression:** While this is an oncological emergency, the primary management is high-dose **Corticosteroids** (Dexamethasone) and often **Decompressive Surgery** (if the spine is unstable or the tumor is radioresistant). Radiotherapy is used urgently, but SVC syndrome is the classic textbook answer for "Emergency Radiotherapy" in this specific MCQ context. **Clinical Pearls for NEET-PG:** * **Most common cause of SVC Syndrome:** Bronchogenic carcinoma (specifically Small Cell Lung Cancer). * **Other Radiotherapy Emergencies:** Hemoptysis, uncontrollable painful bone metastases, and stridor due to airway compression. * **Dose:** Emergency RT often uses "hypofractionation" (larger doses per fraction) to achieve rapid tumor shrinkage.

Question 59: Which of the following tumors is most radiosensitive?

A. Carcinoma of the glottis
B. Carcinoma of the nasopharynx (Correct Answer)
C. Carcinoma of the subglottic area
D. Carcinoma of the thyroid

Explanation: **Explanation:** The radiosensitivity of a tumor is generally determined by its histological type, degree of differentiation, and the rate of cell division (Law of Bergonie and Tribondeau). **Why Carcinoma of the Nasopharynx is correct:** Nasopharyngeal carcinoma (NPC), particularly the **undifferentiated subtype (WHO Type 3)**, is highly radiosensitive. This is due to its high mitotic index and its frequent association with lymphoid stroma (lymphoepithelioma). Because the nasopharynx is surgically inaccessible, **Radiotherapy (RT)** is the primary treatment of choice for all stages of NPC, often yielding excellent local control. **Analysis of Incorrect Options:** * **Carcinoma of the Glottis:** While early-stage glottic cancer is responsive to radiation, it is generally less sensitive than the undifferentiated cells of the nasopharynx. It is often treated with RT to preserve voice function, but the intrinsic sensitivity is lower. * **Carcinoma of the Subglottic Area:** These tumors are often detected late, tend to be more keratinizing/differentiated, and frequently involve the underlying cartilage, making them less responsive to radiation compared to NPC. * **Carcinoma of the Thyroid:** Most thyroid cancers (Papillary and Follicular) are **radioresistant** to external beam radiation. They are primarily managed surgically and with Radioactive Iodine (I-131) therapy, not standard external beam RT. **High-Yield Clinical Pearls for NEET-PG:** * **Most Radiosensitive Tumor:** Seminoma (Male) and Dysgerminoma (Female). * **Most Radiosensitive Normal Cell:** Lymphocyte (exception to the rule that mature cells are resistant). * **Radiosensitivity Scale:** Lymphoma/Leukemia > Squamous Cell Carcinoma > Adenocarcinoma > Sarcoma > Osteosarcoma (highly resistant). * **Nasopharyngeal Ca:** Strongly associated with **EBV (Epstein-Barr Virus)**; the most common site of origin is the **Fossa of Rosenmüller**.

Question 60: What is the quantum of radiation advocated at point A in carcinoma cervix?

A. 8000 cGy (Correct Answer)
B. 1000 cGy
C. 2000 cGy
D. 5000 cGy

Explanation: ***8000 cGy*** - Point A in the **Manchester system** refers to a reference point 2 cm lateral and 2 cm superior to the cervical os, representing the **paracervical tissues** and **uterine vessels**. - The total dose of **8000 cGy** is achieved through a combination of **external beam radiotherapy (EBRT)** (~4500 cGy) and **low-dose rate (LDR) brachytherapy** (~3500 cGy). *1000 cGy* - This dose is significantly **underdosed** for carcinoma cervix and would result in **poor tumor control** and high recurrence rates. - Such low doses are typically used for **palliative treatments** or **benign conditions**, not curative intent in cervical cancer. *2000 cGy* - This dose is still **inadequate** for achieving local control in cervical carcinoma and would lead to **treatment failure**. - It represents less than 25% of the required therapeutic dose for **curative treatment** of cervical cancer. *5000 cGy* - While closer to therapeutic levels, this dose is still **suboptimal** for point A in cervical cancer treatment protocols. - It falls short of the **internationally accepted standard** of 8000 cGy and may result in **suboptimal outcomes** and higher recurrence rates.

Practice by Chapter

Principles of Radiation Therapy

Practice Questions

Radiation Therapy Equipment

Practice Questions

Treatment Planning Process

Practice Questions

External Beam Radiation Therapy

Practice Questions

Brachytherapy

Practice Questions

3D Conformal Radiation Therapy

Practice Questions

Intensity-Modulated Radiation Therapy

Practice Questions

Image-Guided Radiation Therapy

Practice Questions

Stereotactic Radiosurgery

Practice Questions

Total Body Irradiation

Practice Questions

Palliative Radiation Therapy

Practice Questions

Combined Modality Treatments

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free